Genocea target raised on higher GEN-009 odds of success at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated his Buy rating on Genocea Biosciences and raised his price target to $5.75 from $5.00 after increasing his projected chance of success for GEN-009 to 15% from 10% based on the “increasingly strong profile” of the ATLAS platform, as demonstrated most recently at SITC 2018. He also adjusted the share count to account for a recent equity raise and projected impacted from a second tranche of this raise. Pantginis keeps a Buy rating on Genocea.
https://thefly.com/landingPageNews.php?id=2872379